Clinical Trials Logo

Clinical Trial Summary

Prolonged isolated thrombocytopenia (PIT) that is refractory to conventional treatments has remained a critical complication after allogeneic hematopoietic cell transplantation since decades years ago. Recombinant human thrombopoietin (rhTPO) is the main therapy in clinical practice, but remains low efficiency for PIT. Demethylating drugs have shown thier potential in high-risk myelodysplastic syndromes (MDS) and acte myeloid leukemia (AML). In addition, decitabine has demonstrated its efficacy of over 70% for response rate in treatment for PIT in early clinical trials with elusive mechanism. Preliminary experiments revealed that PIT was associated with abnormality of oxidation microenvironment, and N-Acetyl-L-cysteine (NAC) was the most commonly used antioxidant. Therefore, the investigators have been wondering whether Azacitidine in combination with NAC could improve PIT post HSCT and explore the possible mechanism of it.


Clinical Trial Description

Prolonged isolated thrombocytopenia (PIT) that is refractory to conventional treatments has remained a critical complication after allogeneic hematopoietic cell transplantation since decades years ago. Recombinant human thrombopoietin (rhTPO) is the main therapy in clinical practice, but remains low efficiency for PIT. Demethylating drugs have shown thier potential in high-risk myelodysplastic syndromes (MDS) and acte myeloid leukemia (AML). In addition, decitabine has demonstrated its efficacy of over 70% for response rate in treatment for PIT in early clinical trials with elusive mechanism. Preliminary experiments revealed that PIT was associated with abnormality of oxidation microenvironment, and N-Acetyl-L-cysteine (NAC) was the most commonly used antioxidant. Furthermore, AZA had shown its potential in immune regulation. Therefore, the investigators have been wondering whether Azacitidine in combination with NAC could improve PIT post HSCT and explore the possible mechanism of it. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05126004
Study type Interventional
Source The First Affiliated Hospital of Soochow University
Contact Yue Han, PhD,MD
Phone 0512-67781856
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date December 1, 2021
Completion date June 30, 2026

See also
  Status Clinical Trial Phase
Completed NCT03482154 - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Completed NCT03042676 - Electronic Database for the Follow up of the ATG_FamilyStudy
Recruiting NCT03871296 - DNA Methylation in Allogeneic Hematopoietic Stem Cell Transplantation.
Recruiting NCT04502628 - Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT N/A
Recruiting NCT03793517 - Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT Phase 2/Phase 3
Recruiting NCT03454568 - The Patients' Experience After Stem Cell Transplant
Not yet recruiting NCT04080622 - Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation. Phase 3
Completed NCT03355235 - Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant
Completed NCT04888286 - DSAs in Patients Undergoing Allo-HSCT From Mismatched Donors
Active, not recruiting NCT03967665 - Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution Phase 3
Not yet recruiting NCT05104268 - Study of a New Medical Device for Oral Mucositis Phase 1/Phase 2
Recruiting NCT04669210 - PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT Phase 2
Recruiting NCT04623424 - Intestinal Microbiota in Stem Cell Transplant Transplant Admission
Completed NCT03489551 - Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients Phase 4
Enrolling by invitation NCT04106089 - Sleep in Pediatric HSCT N/A
Completed NCT03176849 - A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Phase 4
Completed NCT03533101 - Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation Phase 1/Phase 2
Recruiting NCT04655508 - Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation Phase 3
Recruiting NCT03244930 - Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation Phase 2
Recruiting NCT04194840 - Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT N/A